Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Outperform rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage